Beyond the Obstacles: Zeroing in on AI’s Potential in Healthcare

Paul Darling and Pratap Khedkar


While no technology could address all of the U.S. healthcare system’s woes, artificial intelligence is being positioned to drive real change. ZS’s 2018 AI in Healthcare study set out to determine how far AI has penetrated into U.S. healthcare delivery today, and whether it will get doctors’ and patients’ stamp of approval.

This article shares insights and analysis gleaned through conversations with 400 patients and 400 doctors, as well as several IDN executives and payers. After all, AI’s full entrance into healthcare is predicated on stakeholder consent, and on solving the data use and privacy dilemmas that plague the industry.

About the Experts

Paul Darling is a principal in ZS’s San Francisco office. He assists life sciences companies in evaluating new markets, acquisitions and licensing opportunities, and developing go-to-market strategies. He’s currently exploring opportunities for life sciences companies to take a broader role in patient health in the era of U.S. healthcare reform, including new business and commercial models, therapies, acquisitions and partnerships.

Pratap Khedkar is a managing principal in ZS’s Philadelphia office, and leads the firm’s global pharmaceuticals and data science practices. He has advised many biopharmaceutical and healthcare companies on a wide range of business issues including commercial strategy, customer-centric marketing, market access, sales compensation and advanced analytics. A recognized healthcare industry expert, Pratap regularly contributes his insights to publications including The Wall Street Journal, Bloomberg Businessweek, Business Insider, Fortune, Medical Marketing & Media, NPR, Pharmaceutical Executive and others.